Grace Therapeutics, Inc. Operating Cash Flow
Grace Therapeutics, Inc. (GRCE) reported Operating Cash Flow of -$3.22 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- Grace Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$3.22M.
- Grace Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$1.70M.
- Grace Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$2.23M.
- Grace Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$3.14M.
- Grace Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2026 was -$8.87M.
- Grace Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$14.90M.
- Grace Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$12.33M.
- Grace Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$15.91M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$3.22M 10-Q · filed 2026-08-13 | -$4.92M derived: sum of 2 quarters · filed 2026-08-13 | -$7.15M derived: sum of 3 quarters · filed 2026-08-13 | -$10.29M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | -$1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | -$3.92M derived: sum of 2 quarters · filed 2026-06-18 | -$7.07M derived: sum of 3 quarters · filed 2026-06-18 | -$8.87M 10-K · filed 2026-06-18 | |
| 2025-12-31 | -$2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | -$5.37M derived: sum of 2 quarters · filed 2026-02-12 | -$7.17M 10-Q · filed 2026-02-12 | -$10.13M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-09-30 | -$3.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | -$4.94M 10-Q · filed 2025-11-13 | -$7.90M derived: sum of 3 quarters · filed 2026-08-13 | -$12.01M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | -$1.80M 10-Q · filed 2026-08-13 | -$4.75M derived: sum of 2 quarters · filed 2026-08-13 | -$8.87M derived: sum of 3 quarters · filed 2026-08-13 | -$13.11M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | -$2.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | -$7.07M derived: sum of 2 quarters · filed 2026-06-18 | -$11.31M derived: sum of 3 quarters · filed 2026-06-18 | -$14.90M 10-K · filed 2026-06-18 | |
| 2024-12-31 | -$4.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | -$8.35M derived: sum of 2 quarters · filed 2026-02-12 | -$11.95M 10-Q · filed 2026-02-12 | -$14.04M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-09-30 | -$4.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | -$7.83M 10-Q · filed 2025-11-13 | -$9.92M derived: sum of 3 quarters · filed 2025-11-13 | -$11.81M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | -$3.60M 10-Q · filed 2025-08-12 | -$5.68M derived: sum of 2 quarters · filed 2025-08-12 | -$7.58M derived: sum of 3 quarters · filed 2025-08-12 | -$9.69M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-23 | -$3.98M derived: sum of 2 quarters · filed 2025-06-23 | -$6.09M derived: sum of 3 quarters · filed 2025-06-23 | -$12.33M 10-K · filed 2025-06-23 | |
| 2023-12-31 | -$1.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | -$4.00M derived: sum of 2 quarters · filed 2025-02-13 | -$10.24M 10-Q · filed 2025-02-13 | -$13.57M derived: sum of 4 quarters · filed 2025-02-13 | |
| 2023-09-30 | -$2.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-13 | -$8.35M 10-Q · filed 2024-11-13 | -$11.68M derived: sum of 3 quarters · filed 2024-11-13 | -$15.40M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | -$6.24M 10-Q · filed 2024-08-09 | -$9.57M derived: sum of 2 quarters · filed 2024-08-09 | -$13.29M derived: sum of 3 quarters · filed 2024-08-09 | -$16.73M derived: sum of 4 quarters · filed 2024-08-09 | |
| 2023-03-31 | -$3.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-21 | -$7.05M derived: sum of 2 quarters · filed 2024-06-21 | -$10.49M derived: sum of 3 quarters · filed 2024-06-21 | -$15.91M 10-K · filed 2024-06-21 | |
| 2022-12-31 | -$3.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-12 | -$7.16M derived: sum of 2 quarters · filed 2024-02-12 | -$12.59M 10-Q · filed 2024-02-12 | -$15.73M derived: sum of 4 quarters · filed 2024-02-12 | |
| 2022-09-30 | -$3.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-13 | -$8.87M 10-Q · filed 2023-11-13 | -$12.01M derived: sum of 3 quarters · filed 2023-11-13 | -$16.59M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | -$5.43M 10-Q · filed 2023-08-11 | -$8.57M derived: sum of 2 quarters · filed 2023-08-11 | -$13.15M derived: sum of 3 quarters · filed 2023-08-11 | -$19.26M derived: sum of 4 quarters · filed 2023-08-11 | |
| 2022-03-31 | -$3.15M derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-23 | -$7.73M derived: sum of 2 quarters · filed 2023-06-23 | -$13.83M derived: sum of 3 quarters · filed 2023-06-23 | -$17.23M 10-K · filed 2023-06-23 | |
| 2021-12-31 | -$4.58M 10-Q · filed 2022-02-14 | -$10.69M derived: sum of 2 quarters · filed 2022-02-14 | -$14.09M 10-Q · filed 2023-02-14 | -$15.85M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-09-30 | -$6.10M 10-Q · filed 2021-11-10 | -$9.51M 10-Q · filed 2022-11-14 | -$11.27M derived: sum of 3 quarters · filed 2022-08-11 | -$15.48M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-06-30 | -$3.40M 10-Q · filed 2022-08-11 | -$5.16M derived: sum of 2 quarters · filed 2022-08-11 | -$9.38M derived: sum of 3 quarters · filed 2022-08-11 | -$13.55M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-21 | -$5.97M derived: sum of 2 quarters · filed 2022-06-21 | -$10.15M derived: sum of 3 quarters · filed 2022-06-21 | -$14.32M 10-K · filed 2022-06-21 | |
| 2020-12-31 | -$4.21M 10-Q · filed 2022-02-14 | -$8.39M derived: sum of 2 quarters · filed 2022-02-14 | -$12.56M 10-Q · filed 2022-02-14 | -$35.51M derived: sum of 4 quarters · filed 2022-02-14 | |
| 2020-09-30 | -$4.18M 10-Q · filed 2021-11-10 | -$8.35M 10-Q · filed 2021-11-10 | -$31.29M derived: sum of 3 quarters · filed 2021-11-10 | -$38.40M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | -$4.17M 10-Q · filed 2021-08-12 | -$4.31M 10-Q · filed 2020-08-13 | -$27.11M derived: sum of 2 quarters · filed 2021-08-12 | -$34.22M derived: sum of 3 quarters · filed 2021-08-12 | -$40.37M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$22.94M 10-K · filed 2020-06-29 | -$30.05M derived: sum of 2 quarters · filed 2021-02-09 | -$36.20M derived: sum of 3 quarters · filed 2021-02-09 | -$22.95M 10-K · filed 2021-06-22 | |
| 2019-12-31 | -$7.10M 10-Q · filed 2021-02-09 | -$13.26M derived: sum of 2 quarters · filed 2021-02-09 | -$20.05M 10-Q · filed 2021-02-09 | -$44.87M derived: sum of 4 quarters · filed 2021-02-09 | |
| 2019-09-30 | -$6.15M 10-Q · filed 2020-11-16 | -$12.94M 10-Q · filed 2020-11-16 | -$37.76M derived: sum of 3 quarters · filed 2020-11-16 | ||
| 2019-06-30 | -$6.82M 10-Q · filed 2020-08-13 | -$31.61M derived: sum of 2 quarters · filed 2020-08-13 | |||
| 2019-03-31 | -$24.79M 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |